Cuproptosis-Related Signature Predicts the Prognosis, Tumor Microenvironment, and Drug Sensitivity of Hepatocellular Carcinoma

Xiangjun Qi,Jiayun Guo,Guoming Chen,Caishan Fang,Leihao Hu,Jing Li,Chi Zhang
DOI: https://doi.org/10.1155/2022/3393027
IF: 4.4929
2022-11-18
Journal of Immunology Research
Abstract:Background. Copper (Cu) metabolism is strongly associated with liver disease. Cuproptosis is a novel format of cell death, and cuproptosis-related genes (CRGs) were identified. However, the role of CRGs in Hepatocellular Carcinoma (HCC) remains unknown. Method. The mRNA transcriptome profiling data, somatic mutation data, and copy number gene level data of The Cancer Genome Atlas-Liver Hepatocellular Carcinoma project (TCGA-LIHC) were downloaded for subsequent analysis. Molecular characterization analysis of CRGs, including differential gene expression analysis, mutation analysis, copy number variation (CNV) analysis, Kaplan-Meier analysis, and immune regulator prioritization analysis, was implemented. The nonnegative matrix factorization (NMF) approach was used to identify the CRG-related molecular subtypes. Principal component analysis was adopted to verify the robustness and reliability of the molecular subtype. The least absolute shrinkage and selection operator regression analysis was performed to construct the prognostic signature based on differentially expressed genes between molecular subtypes. The survival characteristics of the molecular subtype and the signature were analyzed. The Gene Set Variation Analysis was performed for functional annotation. The immune landscape analysis, including immune checkpoint gene analysis, single sample gene set enrichment analysis, tumor immune dysfunction and exclusion (TIDE) analysis, immune infiltration cell, and tumor mutation burden analysis (TMB), was conducted. The ability of the signature to predict conventional anti-HCC agent responses was evaluated. The signature was validated in the LIRI-JP cohort and the IMvigor210 cohort. Result. A total of 13 CRGs are differentially expressed between the tumor and normal samples, while the mutation of CRGs in HCC is infrequent. The expression of CRGs is associated with the CNV level. Fourteen CRGs are associated with the prognosis of HCC. Two clusters were identified and HCC patients were divided into 2 groups with a cutoff risk score value of 1.570. HCC patients in the C1 cluster and high-risk have a worse prognosis. The area under the receiver operating characteristic curve for predicting 1-, 2-, and 3-year overall survival is 0.775, 0.768, and 0.757 in the TCGA-LIHC cohort, and 0.811, 0.741, and 0.775 in the LIRI-JP cohort. Multivariate Cox regression analysis indicates that the signature is an independent prognostic factor. Pathways involved in metabolism and gene stability and immune infiltration cells are significantly enriched. Immune checkpoint genes are highly expressed in the C1 cluster. TMB is positively correlated with the risk score. HCC patients in the high-risk group are more likely to benefit from conventional anti-HCC agents and immune checkpoint inhibitor therapies. Conclusion. The molecular characterization of CRGs in HCC is presented in this study, and a successful prognostic signature for HCC based on the cuproptosis-related molecular subtype was constructed.
immunology
What problem does this paper attempt to address?
The problems that this paper attempts to solve mainly focus on the following aspects: 1. **Relationship between copper metabolism and hepatocellular carcinoma**: Copper metabolism is closely related to liver diseases, but its specific role in hepatocellular carcinoma (HCC) remains unclear. This paper aims to explore the molecular characteristics of copper - death - related genes (CRGs) in HCC and their impact on prognosis. 2. **Construction of copper - death - related molecular subtypes**: By analyzing the data of the TCGA - LIHC project, identify the molecular subtypes related to copper death and verify the stability and reliability of these subtypes in different datasets. 3. **Development of copper - death - related prognostic markers**: Based on differentially expressed genes, construct a copper - death - related marker that can predict the prognosis of HCC patients and evaluate the independent prognostic value of this marker. 4. **Evaluation of the application of markers in the immune microenvironment and drug sensitivity**: Analyze the performance of this marker in the tumor immune microenvironment and its ability to predict the treatment response of traditional anti - HCC drugs and immune checkpoint inhibitors. ### Specific research methods and results - **Data preparation**: Download mRNA transcriptome data, somatic mutation data and gene copy number variation data from the TCGA - LIHC project. In addition, validation data were also obtained from the LIRI - JP project and the IMvigor210 cohort. - **Molecular feature analysis**: - **Differential expression analysis**: Use the R software packages limma and ggpubr to generate box plots to compare the expression differences of CRGs in normal and tumor samples. - **Mutation analysis**: Use the R software package maftools to visualize the mutation frequency and type of CRGs. - **Copy number variation analysis**: Use the R software package RCircos to draw the distribution of CRGs on chromosomes and analyze the correlation between CNV and mRNA expression levels. - **Survival analysis**: Use the R software packages survival and survminer to perform Kaplan - Meier analysis to evaluate the prognostic value of a single CRG. - **Construction of copper - death - related molecular subtypes**: - **Non - negative matrix factorization (NMF) clustering analysis**: Use the R software package NMF to perform NMF clustering analysis to determine the number of molecular subtypes. - **Principal component analysis (PCA)**: Verify the stability and reliability of molecular subtypes. - **Construction of copper - death - related prognostic markers**: - **Differential expression gene analysis**: Screen out differentially expressed genes (DEGs) between molecular subtypes. - **LASSO regression analysis**: Use LASSO regression analysis to improve the stability of the model. - **Multivariate Cox regression analysis**: Determine independent prognostic factors and calculate the risk score for each patient. - **Marker verification**: - **Survival analysis**: Verify the prognostic value of the marker in the LIRI - JP cohort. - **ROC curve analysis**: Evaluate the diagnostic performance of the marker. - **Immune microenvironment and drug sensitivity analysis**: Evaluate the performance of the marker in the immune microenvironment and its application in predicting drug sensitivity. ### Main conclusions - Thirteen CRGs that are differentially expressed between tumor and normal samples were identified. - A copper - death - related prognostic marker containing six genes was constructed, and this marker showed good prognostic prediction ability in multiple datasets. - HCC patients in the high - risk group have a poorer prognosis and are more likely to benefit from traditional anti - HCC drugs and immune checkpoint inhibitor treatments. - This study provides new ideas for the molecular typing and individualized treatment of HCC.